At the end of June 2023, ATARA BIOTHERAPEUTICS ($NASDAQ:ATRA) reported their second quarter FY2023 financials, with a 98.1% drop in total revenues year-over-year to USD 1 million. Net income for the quarter was USD -71.1 million, compared to a profit of USD 18.5 million in the same quarter of the previous year.
GoodWhale recently conducted an analysis of ATARA BIOTHERAPEUTICS‘s wellbeing and found that the company is considered a high risk investment based on its Risk Rating. In terms of financial and business aspects, GoodWhale has identified four risk warnings that appear in the firm’s income sheet, balance sheet, cashflow statement, and financial journal. If you would like to learn more about these risk warnings and what they mean for ATARA BIOTHERAPEUTICS, register with us to find out more. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Atara Biotherapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atara Biotherapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atara Biotherapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Atara Biotherapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Some of their competitors are Spectrum Pharmaceuticals Inc, Fate Therapeutics Inc, and vTv Therapeutics Inc. All of these companies work to develop new treatments for various diseases and disorders.
– Spectrum Pharmaceuticals Inc ($NASDAQ:SPPI)
Spectrum Pharmaceuticals is a biotechnology company with a focus on developing and commercializing drugs for the treatment of cancer. The company’s market capitalization is $76.43 million, and its return on equity is -154.18%. Spectrum’s products include oral and injectable drugs for the treatment of leukemia, lymphoma, and multiple myeloma. The company also has a pipeline of investigational drugs in development for the treatment of solid tumors.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders. The company’s lead product candidate is ProTmune, a off-the-shelf programmed cellular immunotherapy for the prevention of graft-versus-host disease. The company is also developing immuno-oncology programs, including FT516, a natural killer cell cancer immunotherapy, and FT819, a universal T-cell cancer immunotherapy.
Fate Therapeutics has a market cap of $1.91 billion as of March 2021. The company’s return on equity (ROE) was negative 28.5% for the same period. Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders. The company’s lead product candidate is ProTmune, a off-the-shelf programmed cellular immunotherapy for the prevention of graft-versus-host disease. The company is also developing immuno-oncology programs, including FT516, a natural killer cell cancer immunotherapy, and FT819, a universal T-cell cancer immunotherapy.
– vTv Therapeutics Inc ($NASDAQ:VTVT)
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of antisense therapeutics. Its marketing products include SPINRAZA, Tegsedi, and Inotersen. The company was founded by Stanley T. Crooke in 1989 and is headquartered in Carlsbad, CA.
ATARA BIOTHERAPEUTICS has recently reported their financials for the second quarter of FY2023, with starkly contrasting results compared to the same period of the previous year. Revenues decreased drastically by 98.1% year-on-year, resulting in a net income of -71.1 million. This is a significant downturn in performance from the 18.5 million profit reported in the same quarter in the previous year. For investors considering investing in ATARA BIOTHERAPEUTICS, this is a stark warning that the company is struggling and market conditions should be taken into account before any investments are made.